Cargando…
A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
BACKGROUND: Cancer heterogeneity poses a serious challenge concerning the toxicity and adverse effects of therapeutic inhibitors, especially when it comes to combinatorial therapies that involve multiple targeted inhibitors. In particular, in non-small cell lung cancer (NSCLC), a number of studies h...
Autores principales: | Li, Yutao, Sharma, Amit, Wu, Xiaolong, Weiher, Hans, Skowasch, Dirk, Essler, Markus, Schmidt-Wolf, Ingo G. H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130779/ https://www.ncbi.nlm.nih.gov/pubmed/35646685 http://dx.doi.org/10.3389/fonc.2022.713476 |
Ejemplares similares
-
NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation
por: Wu, Xiaolong, et al.
Publicado: (2021) -
PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines
por: Li, Yutao, et al.
Publicado: (2021) -
Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer
por: Dehno, Mojgan Naghizadeh, et al.
Publicado: (2020) -
Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells
por: Rombo, Roman, et al.
Publicado: (2016) -
Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma
por: Esser, Laura, et al.
Publicado: (2016)